WILSON JAMES N sold $883K of CORT (indirect holdings)
WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $88.30 ($86.78–$89.49, $0.88M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor insider activity for sentiment, but 10b5-1 sales are typically less informative about near-term fundamentals. Without accompanying company news, the signal is weak.
Market read
A routine insider sale worth ~$883K was disclosed, with no new company-specific catalyst.
What to watch
The article provides only the sale details; it does not include any offsetting buys, changes in other holdings, or new company catalysts that would justify a stronger trading view.
Background
The article is a SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported as an indirect open-market sale by a director under a pre-arranged 10b5-1 plan.
Ticker impact
Corcept Therapeutics director Wilson James N sold about 10,000 shares in an open-market transaction under a 10b5-1 plan, worth ~$883K.
Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.
The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no new operational, financial, or regulatory information disclosed.
Market effects
Minimal. Insider sale in a single name does not imply sector-wide changes.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerCORCEPT THERAPEUTICS INC
Company whose director insider sale is disclosed on Form 4.
- insiderWILSON JAMES N
Director who sold shares indirectly under a 10b5-1 plan.
